Utilization and costs of HIV antiretroviral drugs in Europe during the last ten years: Impact of generic antiretroviral drugs on cost reduction

Since the introduction of Highly Active Antiretroviral Therapy (HAART), HIV infection has become a manageable disease and life expectancy of HIV-infected people considerably increased [1 –4]. However, the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO) noted a stable incidence of HIV infection the last ten years, according to the 2015 report [5] and a significant increase in the number of new HIV cases in Europe the past three year s [6]. The Global Burden of Disease (GBD) study 2015 also reported constant incidence of HIV infection and reduction of mortality in people living with HIV leading to an increase of HIV prevalence [7].
Source: Health Policy - Category: Health Management Authors: Source Type: research